Skip to main content

Table 1 Baseline characteristics of breast cancer patients (stage I-III) at diagnosis and the distribution between those with and without any metabolic comorbidity

From: Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors

Variables Category Overall With any metabolic comorbidity Without any metabolic comorbidity P value
Age (years)   1081 (100%) 606 (56.1%) 475 (43.9%)  
Mean (SD) 50.94 (10.5) 52.5 (10.1) 49.0 (10.7) < 0.001
≤35 77 (7.1%) 58 (7.1%) 50 (10.5%)
36–40 110 (10.2%) 102 (12.4%) 64 (13.5%)
41–55 526 (48.7%) 381 (46.5%) 226 (47.6%)
56–65 277 (25.6%) 201 (24.5%) 106 (22.3%)
> 65 91 (8.4%) 78 (9.5%) 39 (6.1%)
Ethnicity Javanese 1059 (98.0%) 598 (98.7%) 461 (97.1%) 0.06
Non-Javanese 22 (2.0%) 8 (1.3%) 14 (2.9%)
Residence Rural 768 (71%) 426 (70.3%) 342 (72%) 0.540
Urban 313 (29%) 180 (29.7%) 133 (28%)
Menarche (years) ≤12 190 (17.6%) 112 (18.5%) 78 (16.4%) 0.377
13–14 514 (47.5%) 305 (50.3%) 209 (44.0%)
≥15 377 (34.9%) 189 (31.2%) 188 (39.6%)
Menopausal status No (pre-menopause) 306 (28.3%) 137 (22.6%) 169 (35.6%) 0.001
Yes (post-menopause) 775 (71.7%) 469 (77.4%) 306 (64.4%)
Age at menopause ≤50 593 (54.9%) 354 (58.4%) 239 (50.3%) 0.033
> 50 182 (16.8%) 115 (19.0%) 67 (14.1%)
Parity Nulliparous 120 (11.1%) 58 (9.6%) 62 (13.1%) 0.071
Multiparous 961 (88.9%) 548 (90.4%) 413 (86.9%)
Breastfeeding No 216 (20.0%) 114 (18.8%) 102 (21.5%) 0.277
Yes 865 (80.0%) 492 (81.2%) 373 (78.5%)
BMI ≤18.5 136 (12.6%) 49 (8.1%) 87 (18.3%) < 0.001
18.6–25 534 (49.4%) 217 (35.8%) 317 (66.7%)
25.1–30 302 (27.9%) 231 (38.1%) 71 (14.9%)
> 30 109 (10.1%) 109 (18.0%) 0 (0%)  
Family history Yes 199 (18.4%) 99 (16.3%) 100 (21.1%) 0.057
No 882 (81.6%) 507 (83.7%) 375 (78.9%)
Histology grade I 7 (0.6%) 1 (0.6%) 6 (1.2%) 0.058
II 210 (19.4%) 128 (21.1%) 82 (17.3%)
III 864 (79.9%) 477 (78.7%) 387 (81.5%)
Stage I 13 (1.2%) 5 (0.8%) 8 (1.7%) 0.061
II 356 (32.9%) 217 (35.8%) 139 (29.3%)
III 712 (65.9%) 384 (63.4%) 328 (69.1%)
Tumor size ≤ 2 cm 51 (4.7%) 26 (4.3%) 25 (5.3%) 0.038
2–5 cm 311 (28.8%) 193 (31.8%) 118 (24.8%)
>  5 cm 719 (66.5%) 387 (63.9%) 332 (69.9%)
Node status N0 301 (27.8%) 181 (29.9%) 120 (25.3%) 0.220
N1 547 (50.6%) 306 (50.5%) 241 (50.7%)
N2 191 (17.7%) 97 (16.0%) 94 (19.8%)
N3 42 (3.9%) 22 (3.6%) 20 (4.2%)
Adjuvant endocrine therapy No 462 (42.7%) 234 (38.6%) 228 (48.0%) 0.001
Tamoxifen 319 (29.5%) 176 (29.0%) 143 (30.1%)
Aromatase inhibitor 300 (27.8%) 196 (32.3%) 104 (21.9%)
Subtype Luminal-B (N = 497) 497 (46.0%) 297 (59.8%) 200 (40.2%) 0.02
Luminal-B (N = 123) 123 (11.4%) 78 (63.4%) 45 (36.6%)
Her2- enriched (N = 174) 174 (16.1%) 95 (54.6%) 79 (45.4%)
TNBC (N = 287) 287 (26.5%) 135 (47.0%) 152 (53.0%)
(Neo-)/Adjuvant chemotherapy No 92 (8.5%) 39 (6.4%) 53 (11.2%) 0.006
Yes 989 (91.5%) 567 (93.6%) 422 (88.8%)
Adjuvant radiotherapy No 285 (26.4%) 157 (25.9%) 128 (26.9%) 0.700
Yes 796 (73.6%) 449 (74.1%) 347 (73.1%)
Surgery Mastectomy 975 (90.2%) 540 (89.1%) 435 (91.6%) 0.351
BCT 99 (9.2%) 61 (10.1%) 38 (8.0%)
Biopsy 7 (0.6%) 5 (0.8%) 2 (0.4%)
Metabolic comorbidities DM or glucose intolerance 287 (26.5%) 287 (26.5%) 0 (0%)
Dyslipidemia 299 (27.7%) 299 (27.7%) 0 (0%)
Hypertension 464 (42.9%) 464 (42.9%) 0 (0%)
BMI risk (> 27.7) 252 (23.3%) 252 (23.3%) 0 (0%)